Primary facial CD30 positive anaplastic large cell lymphoma：report of one case and review of the literature

doi:10.19438/j.cjoms.2021.04.019

Abstract

Abstract: Primary CD30 positive anaplastic large cell lymphoma is a rare non-Hodgkin's lymphoma. The disease mainly occurs around 60 years old, often in the limbs and trunk. Clinical examination often found tough, well demarcated nodular mass. Histopathological examination showed that a large number of lymphocytes are in the subcutaneous tissue. Morphology combined with immunohistochemical is more effective for diagnosis of this disease. Primary cutaneous ALCL is relatively rare, and primary anaplastic cell lymphoma occuring in the maxillofacial skin is much rare in clinic. In order to improve the diagnosis and treatment of the disease by oral and maxillofacial surgeons, this paper reported a case of ALCL in the maxillofacial skin and review the relevant literatures.

Key words: Lymphoma, CD30⁺ anaplasia, Immunohistochemistry

CLC Number:

R739.8

YANG Cai-xiu, BU Ling-xue, CHEN Li-qiang, FAN Cun-hui, WANG Shuang-yi. Primary facial CD30 positive anaplastic large cell lymphoma：report of one case and review of the literature[J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(4): 380-384.

References

[1] Stein H, Mason DY, Gerdes J, et al.The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells[J]. Blood, 1985, 66(4): 848-858.
[2] Willemze R, Jaffe ES, Burg G, et al.WHO-EORTC classification for cutaneous lymphomas[J]. Blood, 2005, 105(10): 3768-3785.
[3] 代湘云, 吴涛, 白海. 原发性皮肤间变大细胞淋巴瘤治疗进展[J]. 肿瘤学杂志, 2017, 23(8): 711-714.
[4] Lynch RC, Gratzinger D, Advani RH.Clinical impact of the 2016 update to the WHO Lymphoma Classification[J]. Curr Treat Options Oncol, 2017, 18(7): 45-53.
[5] 黄长松, 张婧, 程波, 等. ALK蛋白阴性的原发性皮肤CD30+间变大细胞淋巴瘤[J]. 临床皮肤科杂志, 2018, 47(12): 789-791.
[6] Chen RF, Chen CT, Liao HT, et al.Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis[J]. J Craniofac Surg, 2008, 19(6): 1597-1599.
[7] Montemarano AD, Rowe JE, Benson PM, et al.KI-1 (CD30)-positive anaplastic large cell lymphoma mimicking an infectious granuloma[J]. Int J Dermatol, 1995, 34(11): 790-793.
[8] 侯宇航, 周晋, 赵艳红, 等. 间变大细胞淋巴瘤的临床进展[J]. 现代生物医学进展, 2014, 14(13): 2557-2559.
[9] Sica A, Vitiello P, Ronchi A, et al.Primary cutaneous anaplastic large cell lymphoma (pcALCL) in the elderly and the importance of sport activity training[J]. Int J Environ Res Public Health, 2020, 17(3): 839-851.
[10] Scarisbrick JJ, Calonje E, Orchard G, et al.Pseudocarcinomatous change in lymphomatoid papulosis and primary cutaneous CD30+ lymphoma: a clinicopathologic and immunohistochemical study of 6 patients[J]. J Am Acad Dermatol, 2001, 44(2): 239-247.
[11] Gerami P, Wickless SC, Rosen S, et al.Applying the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in primary cutaneous marginal zone lymphoma[J]. J Am Acad Dermatol, 2008, 59(2): 245-254.
[12] Tomaszewski MM, Moad JC, Lupton GP.Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood[J]. J Am Acad Dermatol, 1999, 40(5 Pt 2): 857-861.
[13] Martín JM, Ricart JM, Monteagudo C, et al.Primary cutaneous CD30+ anaplastic large-cell lymphomas mimicking keratoacanthomas[J]. Clin Exp Dermatol, 2007, 32(6): 668-671.
[14] Kempf W.CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators[J]. J Cutan Pathol, 2006, 33(Suppl 1): 58-70.
[15] Saini S, Dettore AJ, Bhambhani KJ, et al.Selective IgM deficiency in CD30+ cutaneous lymphoproliferative disorder[J]. J Pediatr Hematol Oncol, 2011, 33(4): e156-e159.
[16] Lin JH, Lee JY.Primary cutaneous CD30 anaplastic large cell lymphoma with keratoacanthoma-like pseudocarcinomatous hyperplasia and marked eosinophilia and neutrophilia[J]. J Cutan Pathol, 2004,31(6):458-461.
[17] 吴捷, 彭旭佳, 刘强.复合性原发皮肤间变大细胞淋巴瘤和霍奇金淋巴瘤一例及文献复习[J]. 上海医学, 2009, 32(8):738-740, 762.
[18] Kume M, Kiyohara E, Aoyama R, et al.Primary cutaneous anaplastic large cell lymphoma with rapid liver infiltration after spontaneous resolution of the primary lesion[J]. J Dermatol, 2020, 47(5): e190-e191.
[19] Mencía-Gutiérrez E, Gutiérrez-Díaz E, Salamanca J, et al.Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL)[J]. Int J Dermatol, 2006,45(6):766-769.
[20] Burg G, Kempf W, Kazakov DV, et al.Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature[J]. Br J Dermatol, 2003, 148(3): 580-586.
[21] Sheehy O, Catherwood M, Pettengell R, et al.Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis[J]. Leuk lymphoma, 2009, 50(8): 1389-1391.
[22] de Kan R, van 't Veer MB. Clinical features of CD30 (Ki-1) positive anaplastic large-cell lymphoma (ALCL). Review of the literature[J]. Neth J Med, 1993, 43(5-6): 277-284.
[23] Courville P, Wechsler J, Thomine E, et al.Pseudoepitheliomatous hyperplasia in cutaneous T-cell lymphoma. A clinical, histopathological and immunohistochemical study with particular interest in epithelial growth factor expression. The French Study Group on Cutaneous Lymphoma[J]. Br J Dermatol, 1999, 140(3): 421-426.
[24] Beljaards RC, Kaudewitz P, Berti E, et al.Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients[J]. Cancer, 1993, 71(6): 2097-2104.
[25] Kempf W, Dummer R, Burg G.Approach to lymphoproliferative infiltrates of the skin. The difficult lesions[J]. Am J Clin Pathol, 1999, 111(1 Suppl 1): S84-S93.
[26] Top H, Aygit C, Sarikaya A, et al.Evaluation of maxillary sinus after treatment of midfacial fractures[J]. J Oral Maxillofac Surg, 2004, 62(10): 1229-1236.
[27] Vardiman JW.The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms[J]. Chem Biol Interact, 2010, 184(1-2): 16-20.
[28] Willemze R, Cerroni L, Kempf W, et al.The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas[J]. Blood, 2019, 133(16): 1703-1714.
[29] Reginelli A, Belfiore MP, Russo A, et al.A Preliminary study for quantitative assessment with HFUS (high- frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: interdisciplinary team experience[J]. Curr Radiopharm, 2020, 13(1): 48-55.
[30] Lee WJ, Moon IJ, Lee SH, et al.Cutaneous anaplastic large-cell lymphoma (ALCL): a comparative clinical feature and survival outcome analysis of 52 cases according to primary tumor site[J]. J Am Acad Dermatol, 2016, 74(6): 1135-1143.
[31] Kharfan-Dabaja MA, Kumar A, Ayala E, et al.Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(11): 1826-1838.
[32] Sugiyama H, Asagoe K, Morizane S, et al.Leukocyte common antigen-negative, aggressive cutaneous anaplastic large cell lymphoma with prominent pseudocarcinomatous hyperplasia[J]. Eur J Dermatol, 2008, 18(1): 74-77.
[33] Prince HM, Kim YH, Horwitz SM, et al.Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390(10094): 555-566.
[34] Merli M, Frigeni M, Alric L, et al.Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas[J]. Oncologist, 2019, 24(8): e720-e729.
[35] Welborn M, Duvic M.Antibody-Based therapies for cutaneous T-cell lymphoma[J]. Am J Clin Dermatol, 2019, 20(1): 115-122.
[36] Matutes E.The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms[J]. Int J Lab Hematol, 2018, 40(Suppl 1): 97-103.
[37] 韩颖, 石远凯. 淋巴瘤诊断与治疗的十年回顾[J].实用肿瘤杂志, 2017, 32(6): 483-493.
[38] Liu HL, Hoppe RT, Kohler S, et al.CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma[J]. J Am Acad Dermatol, 2003, 49(6): 1049-1058.
[39] Fauconneau A, Pham-Ledard A, Cappellen D, et al.Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides: a study of 66 cases[J]. Br J Dermatol, 2015, 172(6): 1547-1554.
[40] Parás-Bravo P, Salvadores-Fuentes P, Alonso-Blanco C, et al.The impact of muscle relaxation techniques on the quality of life of cancer patients, as measured by the FACT-G questionnaire[J]. PLoS One, 2017, 12(10): e0184147.
[41] Calogero A, Sagnelli C, Carlomagno N, et al.Familial polyposis coli: the management of desmoid tumor bleeding[J]. Open Med (Wars), 2019, 14: 572-576.